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Long-term antipsychotic polypharmacy
prescribing in secondary mental health care
and the risk of mortality
Kadra G, Stewart R, Shetty H, MacCabe JH, Chang C-K, Taylor D,
Hayes RD Long-term antipsychotic polypharmacy prescribing in
secondary mental health care and the risk of mortality.
Objectives: To investigate the association between long-term
antipsychotic polypharmacy use and mortality; and determine whether
this risk varies by cause of death and antipsychotic dose.
Methods: Using data from a large anonymised mental healthcare
database, we identified all adult patients with serious mental illness
(SMI) who had been prescribed a single antipsychotic or polypharmacy,
for six or more months between 2007 and 2014. Multivariable Cox
regression models were constructed, adjusting for sociodemographic,
socioeconomic, clinical factors and smoking, to examine the association
between APP use and the risk of death.
Results: We identified 10 945 adults with SMI who had been prescribed
long-term antipsychotic monotherapy (76.9%) or APP (23.1%).
Patients on long-term APP had a small elevated risk of mortality, which
was significant in some but not all models. The adjusted hazard ratios
for death from natural and unnatural causes associated with APP were
1.2 (0.9–1.4, P = 0.111) and 1.1 (0.7–1.9, P = 0.619) respectively. The
strengths of the associations between APP and mortality outcomes were
similar after further adjusting for % BNF antipsychotic dose
(P = 0.031) or olanzapine equivalence (P = 0.088).
Conclusion: The findings suggest that the eﬀect of long-term APP on
mortality is not clear-cut, with limited evidence to indicate an
association, even after controlling for the eﬀect of dose.
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Signiﬁcant outcomes
• As compared to long-term antipsychotic monotherapy use, there was a weak association between
long-term antipsychotic polypharmacy use with all-cause mortality and with natural causes of death,
after adjusting for a range of possibly confounders.
• There was no significant association between APP and unnatural causes of death.
• There was no evidence that antipsychotic dose had a direct eﬀect on the risk of death in patients with
serious mental illnesses.
Limitations
• Despite adjusting for a wide array of possible confounders, we were unable to measure factors such
as duration of mental disorder, therefore it is possible that some residual confounding may have
occurred.
• We were unable to examine the association of specific antipsychotic combinations with mortality.
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Introduction
Patients with serious mental illnesses (SMI) have
been estimated to die approximately 15 to 20 years
earlier than the general population (1, 2). The
widespread prescribing of medication regimens not
recommended by existing guidelines (3, 4), such as
antipsychotic polypharmacy (APP), has been sug-
gested to contribute to this increased mortality (5,
6). Furthermore, this risk has been reported to
increase with high-prescribed dose, especially when
exceeding statutory recommendations (7–9). How-
ever, on closer examination, there have been con-
siderable diﬀerences in findings between studies
examining APP, whether of long-term and unspec-
ified duration (5, 6, 10–12). Furthermore, method-
ological problems, such as examining small and
homogenous samples (5, 6) and failure to adjust
for covariates such as dose (11, 12), have resulted
in limited generalizability and possible residual
confounding. Consequently, the association
between APP and serious outcomes such as mor-
tality remains unclear.
The study described here addresses a call for fur-
ther research to examine the risk of outcomes such
as mortality for patients prescribed regular long-
term APP (13, 14). Our aim was to determine
whether there was an association between long-
term use of APP and mortality in a large clinical
cohort, using a de-identified mental health records
database. Furthermore, we set out to investigate
whether this risk varies by cause of death and
whether it was related to antipsychotic dose. We
hypothesised that patients receiving long-term
APP would be at increased risk of all-cause mortal-
ity, in comparison with patients on long-term
monotherapy. We further expected that mortality
would be greater for natural causes of death and
that patients on higher combined dose would have
higher mortality. In addition, we investigated
whether patients on higher doses are at increased
risk of death and the extent to which this
accounted for any associations with APP.
Methods
We constructed a retrospective cohort study, using
anonymised data from South London and Mauds-
ley NHS Foundation Trust (SLAM) electronic
health records (EHR) between 1st January 2007
and 31st December 2014. SLAM is one of the lar-
gest providers of secondary healthcare in Europe,
serving four London boroughs (Lambeth, South-
wark, Lewisham and Croydon) and a population
of approximately 1.36 million (15, 16). The Clinical
Record Interactive Search (CRIS) system was
developed in 2008 to allow researchers to search
and retrieve anonymised SLAM electronic health
records (EHRs). Currently, over 280 000 cases are
represented in the system. CRIS was approved for
secondary analysis by the Oxfordshire Research
Ethics Committee C (reference 08/H606/71+5) in
2008.
Using CRIS, we identified all adults with a diag-
nosis of schizophrenia (ICD-10 code: F20.x),
schizoaﬀective disorder (F25.x) or bipolar disorder
(F31.x), who were in contact with SLAM clinical
services during the observation period. All-cause
mortality was determined through the exact date
of death of patients that had died in the observa-
tion period. We further determined the specific
cause of death for each patient through a data
linkage with the Oﬃce of National Statistics mor-
tality data, a process whereby anonymised BRC
IDs are linked to the death register (16). Causes of
death were categorised into two groups. Unnatural
death included ICD10 diagnosis codes of death:
S00-T98 (injury, poisoning and certain other con-
sequences of external causes); V01-Y98 (external
causes of morbidity and mortality); and U509
(death from injury or poisoning, or event awaiting
determination). All other codes were classified as
natural causes of death.
Antipsychotic medication data were extracted
from SLAM’s pharmacy-dispensing database and
from structured and free-text fields [using a natural
language processing application (NLP)] in the
source health records accessed by CRIS. NLP
applications and features have been used to derive
a large volume of meta-data in CRIS for previous
and current research (16–18). We have described
the procedure for data extraction in detail in a sep-
arate publication (17). All antipsychotic drugs
listed in the British National Formulary 65 were
considered. A long-term APP episode was defined
as the first record of concurrent prescription of
two or more antipsychotics for six or more
months, in the observation window. A detailed
description of how APP was derived is provided in
Kadra et al. (17). If an APP episode was not
recorded, we looked for the first episode of
antipsychotic monotherapy in the observation per-
iod: where a patient was prescribed a single
antipsychotic for six or more months. For each
patient, the follow-up time commenced at the
point they were receiving APP or monotherapy for
six or more months (index date). Follow-up con-
tinued until a death was recorded or the end of the
observation period (31st December 2014), which-
ever occurred first.
Information on antipsychotic dose was extracted
from free-text, using natural language processing
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(NLP) and structured fields, for both antipsychotic
monotherapy and polypharmacy, where such
information was available. APP cases where dose
was not available for all antipsychotics that were
part of the polypharmacy were not included. The
authors calculated the positive predictive value (i.e.
precision) for antipsychotic dose at 0.8, in this
study.
Dose was calculated at the index date using two
diﬀerent methods. In the UK, percentage out of
maximum BNF recommended dose (%BNF) is
recommended by the Royal College of Psychia-
trists (19) and was calculated by converting the
dose of each drug into a percentage of the BNF
maximum recommended dose for that drug. For
APP, the percentages for individual antipsychotics
were added together into a summed value. A
cumulative dose of more than 100% was consid-
ered a high dose (19). A likelihood ratio test indi-
cated that it was appropriate to use this as a
continuous variable in the analysis. In addition, we
also calculated olanzapine equivalence (20) by add-
ing up the equivalence doses of all antipsychotics
that were part of the polypharmacy regimen. A
total dose above 20 milligrams (mg) was classified
a high dose (20, 21). A likelihood ratio test indi-
cated that it was most appropriate to use this vari-
able as categorical, where 1–10 mg was identified
as a low dose, 11–20 mg as medium dose and
21 mg or above as high dose.
Age, gender, ethnicity and relationship status
were derived from structured fields, closest to the
index date. A likelihood ratio test indicated that it
was appropriate to use age as a continuous vari-
able in the analysis. Seventeen ethnic groups were
collapsed into six categories due to small numbers
in some cells. Relationship status was categorised
as in ‘relationship’ (cohabitating, married or civil
partnership) and ‘no relationship’ (single,
divorced, separated, widowed, unknown). We used
a neighbourhood-level index of multiple depriva-
tion to estimate socioeconomic status based on
seven domains of deprivation ascertained from
2007 UK Census estimates (employment, income,
education, health, barriers to housing and services,
crime and living environment). Multiple depriva-
tion indices were weighted and combined into an
overall score applied to lower super output geo-
graphical areas (LSOAs), each containing on aver-
age 1500 residents (22). LSOAs were categorised in
tertiles in the analysis. In addition, homelessness
(23) was ascertained based on ‘no fixed abode’
codes.
Clinical covariates included comorbid diagnoses
of depression (ICD-10: F32, F33), personality dis-
order (ICD-10: F60-61), or substance use (ICD-10:
10-16), prior to or at the point follow-up began.
We ascertained this using information available
from free-text (such as progress notes) and struc-
tured fields (from drop down menus). In addition,
we identified the lengths of time in days that each
patient was known to SLAM services at the index
date, by examining all structured and free-text
records available since 1st January 2007 up until
the point the patient qualified for the APP or
monotherapy group. A likelihood ratio test indi-
cated that it was appropriate to enter this as a con-
tinuous variable in the analysis. Given the
increased risk of mortality amongst smokers (24,
25), patients were classified into two groups,
those who have never smoked and past or current
smokers.
Statistical analysis
STATA 13 (StataCorp LP, College Station, TX,
USA) was used to conduct all statistical analyses.
Sample characteristics were summarised for the
total cohort, as well as for all those who were in
the long-term APP and monotherapy group. Cox
proportional hazard ratios were used to determine
whether any of the covariates were significantly
associated with all-cause mortality. We further
used chi-square tests to investigate whether the
monotherapy and APP group diﬀered in relation
to their sample characteristics. Kaplan–Meier
curves with a log-rank test were used to compare
those who were prescribed APP and monotherapy
in relation to all-cause mortality. Following checks
of proportional hazards assumptions, Cox regres-
sion procedures were used to examine the associa-
tions between antipsychotic regimen and risk of
death.
Multivariable models included potential con-
founders such as age, gender, ethnicity, relation-
ship status, deprivation status, comorbid
diagnoses, time known to SLAM and smoking.
Two additional fully adjusted models including %
BNF and olanzapine equivalence dose, respec-
tively, were also run. To reduce the eﬀect of con-
founding by indication, we used a standard
propensity score method, where the propensity
score was the probability of being placed on APP
based on all variables described above (apart from
dose). Dose was not included in calculating the
propensity score due to not having available dose
information for all patients in the cohort. The
propensity scores were built through a regression
model, which included all covariates. We then
included the propensity score as a covariate in
place of all of the aforementioned confounders in
the Cox model. To examine the risk for cause-
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specific mortality, we used competing risk regres-
sion analyses, which allows for more than one
competing risk in the cohort (e.g. diﬀerent causes
of death).
Results
We identified 10 945 individuals who met the
inclusion criteria for the study. The mean time of
follow-up was 1636 days (standard devia-
tion = 839), which is approximately four and a
half years. Table 1 summarises the sample charac-
teristics by antipsychotic monotherapy and
polypharmacy group. In total, 8421 (76.9%) sam-
ple cases were prescribed long-term monotherapy,
of whom 758 (9%) died in the follow-up. A further
2524 sample cases (23%) were prescribed long-
term APP, of whom 162 (6.4%) died. Out of the
patients who were prescribed long-term APP and
died, 44 (27%) were on APP just prior to their
death (results not shown). Patients prescribed
monotherapy diﬀered significantly from those pre-
scribed APP across all sociodemographic, socioe-
conomic, clinical and smoking characteristics
apart from comorbid substance use, where a com-
parable proportion of patients received a comorbid
substance use diagnoses. Patients prescribed APP
were on average younger, more likely to be of
Black African or Caribbean ethnicity, less likely to
be in a relationship or employed and living in a
higher deprivation neighbourhood. Furthermore,
patients receiving APP were more likely to be diag-
nosed with schizophrenia, whereas patients on
monotherapy had a higher prevalence of bipolar
aﬀective disorder diagnosis. Patients on monother-
apy were more likely to have a comorbid depres-
sion diagnosis, whereas patients on APP had a
higher prevalence of personality disorders. Patients
receiving APP were known to the source mental
health service for longer, were more likely to
receive a high antipsychotic dose (as measured by
both %BNF and olanzapine equivalence) and were
more likely to have ever smoked.
Table 2 describes the characteristics of the total
cohort, together with an age and gender adjusted
Cox regression analysis of the association between
death and sample characteristics. In total, 920
(8.4%) patients died within the observation win-
dow. Age, male gender, comorbid substance use
and having ever smoked were all associated with
an increased risk for all-cause mortality, whereas
being in a relationship at the time the follow-up
began or being of Black African or Caribbean eth-
nicity was associated with a lower risk.
Figure 1 displays the Kaplan–Meier curves com-
paring mortality over time for patients prescribed
either long-term antipsychotic monotherapy or
polypharmacy. There was no significant diﬀerence
in mortality across the two groups over time
(P = 0.166).
Table 3 summarises Cox proportional hazards
models of the associations between long-term APP
(compared to long-term monotherapy) and all-
cause mortality. Age and gender appeared to have
a negative confounding eﬀect, and adjusting for
Table 1. Sample characteristics of patients prescribed monotherapy and antipsy-
chotic polypharmacy (n = 10 945)
Variables
Monotherapy*
n (%)
Antipsychotic
polypharmacy* n (%)
Total 8421 (76.9) 2524 (23.1)
Sociodemographic and socioeconomic factors
Age mean (SD) 42.2 (15.4) 38.1 (13.5)
Gender
Female 3737 (44.4) 1054 (41.8)
Male 4684 (55.6) 1470 (58.2)
Ethnicity group
British 3160 (37.6) 838 (33.2)
Other White 791 (9.4) 184 (7.3)
Asian 566 (6.7) 159 (6.3)
Caribbean 1072 (12.7) 354 (14.0)
Black African 2198 (26.1) 813 (32.2)
Other 634 (7.5) 176 (7.0)
Employment
Not in paid employment 8132 (96.6) 2461 (97.5)
Paid employment 289 (3.4) 63 (2.5)
Relationship status
No relationship 7198 (85.5) 2303 (91.2)
Relationship 1223 (14.5) 221 (8.8)
Deprivation level in area of residence
Low level 2726 (32.6) 805 (32.2)
Medium level 2758 (33.0) 808 (32.3)
High level 2742 (32.8) 821 (32.9)
Homelessness 135 (1.6) 65 (2.6)
Clinical factors
Schizophrenia (ICD-10: F20) 5896 (70.0) 1950 (77.3)
Schizoaffective disorder (ICD-10: F25) 639 (7.6) 235 (9.3)
Bipolar affective disorder (ICD-10: F31) 1886 (22.4) 339 (13.4)
Comorbid depression (ICD-10: F32-33)
No 7235 (85.9) 2223 (88.1)
Yes 1186 (14.1) 301 (11.9)
Comorbid personality disorder (ICD-10: F60-61)
No 7642 (90.8) 2145 (85.0)
Yes 779 (9.2) 379 (15.0)
Comorbid substance use* (ICD-10: F10-16)
No 7581 (90.0) 2252 (89.2)
Yes 840 (10.0) 272 (10.8)
Time known to SLAM (days)
Mean (SD) 1603.5 (1138.2) 2223.9 (1468.9)
%BNF
Mean (SD) 45.8 (36.8) 101.8 (68.8)
Olanzapine equivalence dose
1–10 mg 4341 (55.7) 134 (6.0)
11–20 mg 2427 (31.2) 557 (25.0)
21 + mg 1022 (13.1) 1536 (69.0)
Smoking
Never smoked 3016 (35.8) 374 (14.8)
Have smoked ever 5405 (64.2) 2150 (85.2)
*There was a significant difference between groups for all factors, apart from
comorbid substance use (P = 0.242).
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those in the multivariable model increased the
strength of the association of interest. However,
adjusting the model for smoking status resulted in
a decrease in the hazard ratio for mortality and the
association was no longer statistically significant.
The fully adjusted model indicated a slightly ele-
vated risk, but this was not statistically significant.
The association remained unchanged after we
adjusted for propensity scores, in place of the
above factors. Antipsychotic dose information was
available for 92% of the sample; therefore the total
cohort sample for the analysis including %BNF
dose was n = 10 022. Gardner et al. (26), do not
provide an olanzapine equivalent dose for asenap-
ine, therefore five further cases were dropped
resulting in n = 10 017 for the analysis including
olanzapine equivalence dose. We included %BNF
and olanzapine equivalence dose as covariates in
two separate models. The %BNF dose adjustment
resulted in a modest significant association
between APP prescribing and mortality; however,
this association was not significant in the model
where olanzapine equivalence was included as a
covariate.
Table 3 further summarises the crude and fully
adjusted competing risk regression analyses of the
associations between being prescribed long-term
APP, natural and unnatural causes of death. Cause
of death was available for 892 (97%) of all deaths
recorded for the monotherapy and APP groups.
For natural causes of death, adjusting for possible
confounders indicated a modest eﬀect of APP,
which did not reach statistical significance. To
examine the eﬀect of dose, we conducted a stratifi-
cation (results not shown), which indicated a sig-
nificant interaction between antipsychotic dose
and APP for natural causes of death. A crude
stratification of APP by dose indicated that APP in
patients receiving high dose treatment [for both %
BNF (HR: 0.6, 95% CI: 0.4–0.9) and olanzapine
equivalence (HR: 0.6, 0.4–0.8)] was associated with
a lower risk for natural causes of death. However,
this association was not maintained in the fully
adjusted models, either for %BNF (HR: 1.4, 0.8–
2.3) or olanzapine equivalence (HR: 1.1, 0.8–1.0)
as dose measures. We further included %BNF and
olanzapine equivalence dose as covariates in two
Table 2. Cox regression analysis of the association between sample characteristics
and all-cause mortality hazard (n = 10 945; 920 deaths)
Variables n (%) HR (95% CI)*
Sociodemographic and socioeconomic factors
Age
Mean (SD) 57.4 (17.0) 1.1 (1.06–1.07)
Gender
Female 427 (46.4) Reference
Male 493 (53.6) 1.4 (1.2–1.6)
Ethnicity group
British 468 (50.9) Reference
Other White 91 (9.9) 0.8 (0.6–1.0)
Asian 54 (5.9) 0.8 (0.6–1.0)
Caribbean 140 (15.2) 0.7 (0.6–0.9)
Black African 129 (14.0) 0.8 (0.7–0.9)
Other 38 (4.1) 0.8 (0.6–1.2)
Relationship status
No relationship 808 (87.8) Reference
Relationship 112 (12.2) 0.8 (0.6–0.9)
Employment
Not in paid employment 910 (98.9) Reference
Paid employment 10 (1.1) 0.6 (0.3–1.1)
Deprivation level in area of residence
Low level 328 (35.7) Reference
Medium level 299 (32.8) 1.0 (0.9–1.2)
High level 283 (30.9) 0.9 (0.8–1.1)
Homelessness 5 (0.6) 0.6 (0.2–1.4)
Clinical factors
Diagnosis
Schizophrenia (ICD-10: F20) 690 (75.0) Reference
Schizoaffective disorder (ICD-10: F25) 60 (6.5) 0.9 (0.7–1.2)
Bipolar Affective Disorder (ICD-10: F31) 170 (18.5) 0.9 (0.8–1.1)
Comorbid Depression (ICD 10: F32-33)
No 816 (88.7) Reference
Yes 104 (11.3) 0.9 (0.7–1.2)
Comorbid Personality Disorder (ICD 10: F60-61)
No 858 (93.3) Reference
Yes 62 (6.7) 1.2 (0.9–1.6)
Comorbid Substance Use (ICD 10: F10-16)
No 835 (90.8) Reference
Yes 85 (9.2) 1.7 (1.3–2.1)
Time known to SLAM (days)
Mean (SD) 1667.15 (996.7) 1.0 (0.9999–1.0000)
%BNF
Mean (SD) 53.95 (49.7) 1.0 (0.9991–1.0017)
Olanzapine equivalence dose
1–10 mg 373 (45.5) Reference
11–20 mg 211 (25.7) 0.9 (0.8–1.2)
21 + mg 236 (28.8) 1.1 (0.9–1.3)
Smoking
Never smoked 301 (32.7) Reference
Have smoked ever 619 (67.3) 1.5 (1.3–1.8)
Bold indicates statistically significant value (P < 0.05).
*All HR have been age and gender adjusted.
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Fig. 1. Kaplan–Meier survival curve comparing mortality
over time of patients prescribed either long-term antipsychotic
monotherapy or polypharmacy (n = 10 945).
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separate models. Similar to the models for all-
cause mortality, the %BNF dose adjustment
revealed a modest significant association between
APP prescribing and natural causes of death, this
association was not significant in the model where
olanzapine equivalence was included as a covari-
ate.
Table 3 also summarises the crude and fully
adjusted competing risk regression analysis for
unnatural causes of death and long-term APP. We
found no evidence to suggest that long-term APP
prescribing was associated with a change in risk
for unnatural causes of death. Percentage BNF
and olanzapine equivalence dose were included,
sequentially in the fully adjusted model. The
results indicated that dose had little eﬀect on the
overall association.
Table 4 summarises the crude and fully adjusted
Cox regression analyses between antipsychotic
dose and the risk for all-cause mortality. We found
no association between dose and the risk of death
for patients with SMI. The results were very simi-
lar for both %BNF and olanzapine equivalence
dose definitions.
Discussion
To our knowledge, this is the first study to investi-
gate the association between regular long-term
APP use (as opposed to APP which is due to pro re
nata, cross-titration or switching) and all-cause
and cause-specific mortality, taking advantage of a
large and diverse cohort and adjusting for multiple
confounders, in addition to investigating the eﬀects
of combined antipsychotic dose. We hypothesised
that as compared to long-term antipsychotic
monotherapy use, long-term APP would be associ-
ated with an increased risk for all-cause mortality
and specifically of death from natural causes. The
results indicated a weak association between long-
term antipsychotic polypharmacy use with all-
cause mortality and with natural causes of death,
after adjusting for gender and age. Although these
associations were not markedly confounded by
other factors, the fully adjusted hazard ratios fell
below statistical significance. There was no signifi-
cant association between APP and unnatural
causes of death. Also, there was no evidence that
antipsychotic dose had a direct eﬀect on the risk of
death in this sample with SMI.
Table 3. Multivariate Cox regression analysis of the association between antipsy-
chotic polypharmacy prescribing and mortality in individuals with serious mental ill-
ness. (n = 10 945)
Models
Antipsychotic
polypharmacy vs.
monotherapy
HR (95% CI) P value
Unadjusted model 0.9 (0.7–1.1) P = 0.166
Model adjusted for age and gender 1.2 (1.0–1.5) P = 0.016
Model adjusted for socio-demographic†
and socioeconomic‡ factors
1.2 (1.0–1.5) P = 0.020
Model adjusted for age, gender and clinical factors § 1.2 (1.0–1.5) P = 0.017
Model adjusted for age, gender and smoking 1.1 (0.9–1.4) P = 0.111
Fullyadjusted model¶ 1.2 (0.9–1.4) P = 0.079
Fully adjusted model using propensity
score as a covariate¶
1.2 (0.9–1.4) P = 0.084
Fully adjusted model and %BNF dosek¶ 1.3 (1.0–1.5) P = 0.031
Fully adjusted model and olanzapine
equivalence dose††¶
1.2 (0.9–1.5) P = 0.088
Natural causes of death HR (95% CI) P value
Unadjusted model 0.8 (0.7–1.0) P = 0.062
Fully adjusted model¶ 1.2 (0.9–1.4) P = 0.111
Fully adjusted model and %BNFk¶ 1.3 (1.0–1.6) P = 0.040
Fully adjusted model and Olanzapine
equivalence dose††¶
1.2 (0.9–1.5) P = 0.166
Unnatural causes of death HR (95% CI) P value
Unadjusted model 1.1 (0.7–1.8) P = 0.601
Fully adjusted model¶ 1.1 (0.7–1.9) P = 0.619
Fully adjusted model and %BNFk¶ 0.9 (0.6–1.7) P = 0.960
Fully adjusted model and Olanzapine
equivalence dose††¶
1.1 (0.6–1.9) P = 0.821
Bold indicates statistically significant value (P < 0.05).
†Sociodemographic factors included age, gender, ethnicity, relationship status.
‡Socioeconomic factors included employment and deprivation level.
§Clinical factors comprised comorbid depression (ICD-10: F32-33), personality disor-
der (ICD-10: F60-61) and substance use (ICD-10: F10-16); and time known to SLAM
services (days).
¶Includes all of the above.
kAntipsychotic dose information was available for 92% of the sample; therefore the
total cohort sample for the analysis including %BNF dose was n = 10 022.
††Gardner et al. (26), do not provide an olanzapine equivalent dose for asenapine,
therefore the total cohort sample for the analysis was n = 10 017.
Table 4. Multivariable Cox analysis of the association between all-cause mortality
and antipsychotic polypharmacy dose
Dose calculated as %BNF† HR (95% CI) P value
Unadjusted model 1.0 (0.997–1.000) P = 0.064
Fully adjusted model‡ 1.0 (0.999–1.001) P = 0.996
Dose calculated as olanzapine equivalence HR (95% CI) P value
1–10 mg Reference group
11–20 mg
Unadjusted model 0.8 (0.7–0.9) P = 0.018
Fully adjusted model‡ 0.9 (0.8–1.1) P = 0.532
21 + mg
Unadjusted model 1.1 (0.9–1.3) P = 0.296
Fully adjusted model‡ 1.1 (0.9–1.3) P = 0.377
Bold indicates statistically significant value (P < 0.05).
†%BNF used as continuous variable.
‡Factors included: age, gender, ethnicity, relationship status, employment, depriva-
tion level, comorbid depression (ICD-10: F32-33), personality disorder (ICD-10: F60-
61) and substance use (ICD-10: F10-16), time known to SLAM services (days) and
smoking.
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In keeping with existing literature, we found that
patients prescribed APP were younger, less likely
to be employed, less likely to be in a relationship,
had a higher proportion of schizophrenia diagnosis
and were known to services for longer, in compar-
ison with patients on monotherapy (27–29). How-
ever, apart from gender and age, the
aforementioned factors seemed to have small
eﬀects on the association between long-term APP
and all-cause mortality.
Overall, the literature to date examining APP
and the risk of death in SMI has been mixed and
inconclusive. There has been some evidence from
research investigating APP of unspecified duration,
indicating that APP increases the risk for death (5,
30). However, findings from larger epidemiological
studies have been mixed, with evidence to indicate
no association (12) and possibly lower risk for
mortality (11) in patients prescribed APP com-
pared to those on monotherapy. Our findings fur-
ther indicate that the risk in the SMI cohort we
examined is not clear-cut. There did appear to be a
small eﬀect of long-term APP on all-cause mortal-
ity based on the eﬀect estimates, which remained
consistent across most models; however, this asso-
ciation was relatively weak and did not reach sta-
tistical significance in the fully adjusted model.
People with schizophrenia have an increased risk
for premature death from natural causes such as
cardiovascular diseases (31–33) and unnatural
causes such as suicide (34, 35) compared with the
general population. Risks arising from pharma-
cotherapy are an obvious concern, particularly
when pharmacotherapy regimens are outside stan-
dard guidance; however, research examining the
eﬀect of long-term APP prescribing on cause-speci-
fic mortality has been extremely sparse. Bandura
and colleagues (10) examined antipsychotic
polypharmacy in the ninety days prior to death and
reported that the risk for natural causes of death
did not increase when patients were prescribed two
or more antipsychotics, as compared with
monotherapy. In our study, although the findings
did not indicate a statistically significant diﬀerence
between patients prescribed APP and monotherapy
in most models, the modest eﬀect estimate for the
relationship between APP on the risk for natural
causes of death remained consistent, once we
adjusted for gender and age. Associations between
long-term APP and unnatural cause of death were
weaker and not statistically significant.
In line with existing literature (13, 36, 37),
patients prescribed long-term APP were more
likely to be prescribed a higher combined dose of
antipsychotics in comparison with patients on
long-term monotherapy. Adjusting for dose had
little eﬀect on the association between APP and
mortality apart from a small change after adjusting
for %BNF. Some previous research has indicated
that high antipsychotic dose is associated with
increased risk for all-cause mortality, and more
specifically for cancer, cardiovascular and respira-
tory causes of death (7, 32, 38). There are several
possible explanations for discrepancies between
studies. It is possible that diﬀerent methods of cal-
culating antipsychotic dose would yield slightly
diﬀerent results. Methods such as %BNF dose and
defined daily dose (DDD) are calculated using the
upper licensed dose range of antipsychotics (21).
This poses a problem for antipsychotics that reach
their maximum eﬃcacy at a lower dose range, such
as risperidone (e.g. 3–6 mg a day when the maxi-
mum is 16 mg, or quetiapine widely used at
600 mg when the maximum is 750 mg), and which
are thus rarely prescribed at maximum or above
maximum recommended dose. Furthermore, over
the years, there have been changes to the recom-
mended maximum doses for some antipsychotics
that make it diﬃcult to compare findings from dif-
ferent studies across time. Therefore, it is possible
that this approach oﬀers a less robust measure of
dose in comparison with the olanzapine equiva-
lence method. An alternative explanation for dif-
ferences in findings across studies is the possibility
of residual confounding. For example, although
Torniainen et al. (7) used age and gender-matched
case and controls, their Cox model did not account
for any other factors that may aﬀect mortality such
as smoking, which is associated with significant
risk for death (24, 39).
This study had several strengths. SLAM is a
near-monopoly mental health care provider for its
geographic catchment (15, 16); therefore, we were
able to capture a large cohort of patients with SMI
giving us the statistical power to adjust for a num-
ber of potential confounders, such as smoking and
antipsychotic dose, that other research has been
unable to examine. At present, there is no ‘gold
standard’ of calculating equivalent doses (21);
therefore we chose to use two diﬀerent methods.
This gave us an opportunity to test the eﬀect of
dose more rigorously and also demonstrate that
existing evidence in this field needs to be inter-
preted with caution, as findings are dependent on
the method that is used.
There are several potential limitations that need
to be borne in mind when drawing conclusions. It
is possible that we did not have suﬃcient statistical
power to detect a consistently significant eﬀect
across all models. Furthermore, despite adjusting
for multiple confounders, it is possible that some
residual confounding may have occurred. For
7
Antipsychotic polypharmacy and risk of mortality
example, we were unable to measure and adjust for
the duration of mental disorder. In addition, we
were unable to determine the antipsychotic regi-
men just prior to death or any changes in prescrib-
ing in the lead up to patient’s death. Consequently,
we could not account for the eﬀect of the duration
of the prescribed regimen on death. In addition,
we were unable to examine the acute eﬀects of
antipsychotic regimens. Although this could have
resulted in immortal time bias, as the patients had
to survive long enough to enter either of the expo-
sure groups, we took the following measures the
follow-up time for both exposure and control
group commenced at the point patients were
receiving APP or monotherapy for six or more
months, therefore both groups entered the cohort
after the six months mark in their treatment. In
relation to confounders, the role of smoking as a
covariate does need to be considered with some
caution. Adjustment for smoking presupposes a
situation where people who go on to receive APP
have more unhealthy lifestyles, including smoking,
which account for any raised mortality in this
group. However, it is possible that an eﬀect of
APP may be to maintain smoking behaviour, if
this is used to counteract perceived or actual
adverse eﬀects of medication (40). Inclusion of
smoking as a covariate in this circumstance would
represent an overadjustment. Unfortunately, it was
not possible to tease out the timing of APP in rela-
tion to smoking status, and therefore these diﬀer-
ent pathways have yet to be distinguished.
Furthermore, examining specific combinations of
antipsychotics was beyond the scope of the study.
To conclude our findings suggest that the eﬀect
of long-term APP on mortality is not a clear-cut
one. This has potential implications for further
research. It is possible that if there is an eﬀect on
mortality, this is driven by specific antipsychotic
medication combinations. Therefore, future
research could focus on examining common
antipsychotic combinations and their eﬀect on par-
ticular cause of death, such as cardiovascular death
(41). Furthermore, our findings need to be inter-
preted within the wider clinical and treatment con-
text. Despite the lack of a consistent significant
eﬀect of APP on mortality, when prescribing this
regimen it is important to bear in mind that APP
continues to be associated with more severe side-
eﬀects (42, 43). In addition, the notion that more is
better, in relation to adding additional antipsy-
chotics and increasing treatment dose, has been
consistently rejected by empirical research (44),
indicating that once an optimal dose and response
is reached, adding additional treatments makes lit-
tle diﬀerence. Lastly, evidence remains that APP is
often prescribed in favour to clozapine monother-
apy, despite research indicating that clozapine is
eﬀective in treating treatment-resistant symptoms
(45). This is likely to reflect a prescribing culture
rather than evidence-based treatment (45) and a
need to target this on prescriber and service level
remains (46, 47).
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